A cervicofaciális actinomycosisok jellemzői és korszerű diagnosztikája: összefoglaló az irodalmi adatok alapján

Abstract

Humán infekciókban igazolt patogén szerepben leírt Actinomyces fajok A. bovis A. graevenitzii A. nasicola A. radingae A. cardiffiensis A. hominis A. neuii A. timonensis A. dentalis A. hongkongiensis A. odontolyticus A. turicensis A. europaeus A. israelii A. oris A. urogenitalis A. funkei A. massiliensis A. oricola A. viscous A. georgiae A. meyeri A. pyogenes számos, még nem definiált geno-species A. gerencseriae A. naeslundii A. radicidentis A félkövér betűvel jelzett fajok okozzák a humán infekciók több mint 90%-át. Az A. odontolyticus és az A. meyeri a cervicofaciális régióban a leggyakoribb, míg az A. gerencseriae és az A. israelii minden más anatómiai régióban jelentős. Az actinomycosisok diagnosztikai algoritmusának összefoglalása FOGORVOSI SZEMLE 113. évf. 3. sz. 2020. n 104 A 2020. évben végzett fogorvostan-hallgatók doktorrá avatása cytology of cervicofacial actinomycosis.

Microbiological and Clinical Aspects of Actinomyces Infections: What Have We Learned?

“…The genus name "Actinomyces" originates from the Greek words "aktina" («ακτίνα») (ray) and "mykis" («µύκης») (fungus), which aims to symbolize the arrangement of the bacterial filaments, which may frequently be observed with microscopy [8]. As of now, there have been 26 individual Actinomyces species implicated in human clinical infections (actinomycoses), with A. odontolyticus, A. meyeri, A. israelii, and A. gerencseriae responsible for more than 90% of these infections [9,10]. Most cases (40-60%) of actinomycoses affect the cervicofacial region and the central nervous system (CNS), while abdominal (20-30%), thoracic/pulmonary (20-30%), pelvic (3-5%), and cutaneous (3-5%) manifestations must also be considered [9][10][11][12][13].…”

“…As of now, there have been 26 individual Actinomyces species implicated in human clinical infections (actinomycoses), with A. odontolyticus, A. meyeri, A. israelii, and A. gerencseriae responsible for more than 90% of these infections [9,10]. Most cases (40-60%) of actinomycoses affect the cervicofacial region and the central nervous system (CNS), while abdominal (20-30%), thoracic/pulmonary (20-30%), pelvic (3-5%), and cutaneous (3-5%) manifestations must also be considered [9][10][11][12][13]. The clinical diagnosis of actinomycosis may be quite difficult: the clinical presentation of the patient, past medical history (injuries, immunosuppression, cancers), laboratory parameters, microbiological culture, and histopathology must all be taken into consideration, as this disease frequently mimics a malignancy or infection by other bacteria (e.g., Nocardia, mycobacteria) [11][12][13].…”